Neurometa Therapeutics ApS
CVR 44557703 · Private limited company (ApS) · Active · High risk
Neurometa Therapeutics ApS is a Private limited company (ApS), founded on , based in Aalborg Øst. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 5.9% over the next 12 months, which is 4.2 times the average for Danish companies. 2 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -264k and a net result of DKK -19k. CEO: Preben Bruun-Nyzell, Josephus Dirk Vestergaard Nieland, Steinunn Sara Helgudóttir.
Bankruptcy risk for Neurometa Therapeutics ApS
4.2 × the average (1.41%) · higher risk than 93% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 44557703
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (2 years)
- Address
- Kaolinvej 5
9220 Aalborg Øst - Municipality
- Aalborg
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 40k
- Auditor
- Deloitte Statsautoriseret Revisionspartnerselskab
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 1 of 2 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -461.2% |
| Current ratio | 18% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 1 |
| CEO's previous bankruptcies | 2 |
| Other companies at the address | 3 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -17k | DKK -32k |
| Net profit | DKK -19k | DKK -286k |
| Equity | DKK -264k | DKK -246k |
| Total assets | DKK 57k | DKK 77k |
| Cash | DKK 57k | – |
| Short-term debt | DKK 322k | – |
| Avg. employees | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · Deloitte Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 187 | Late | |
| 2 Jan 2024 – 31 Dec 2024 | 182 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Preben Bruun-Nyzell | Current | |
| CEO | Josephus Dirk Vestergaard Nieland | Current | |
| CEO | Steinunn Sara Helgudóttir | Current | |
| CEO | Anne Skøttrup Mørkholt | ||
| Owner (100%) | Neurometa Therapeutics AB | Current | |
| Owner (20%) | Helgudottir Holding ApS | ||
| Owner (20%) | AKGM Holding ApS | ||
| Owner (33%) | J&P Pharma Holding AB | ||
| Founder | Helgudottir Holding ApS | Current | |
| Founder | AKGM Holding ApS | Current | |
| Founder | J&P Pharma Holding AB | Current |
The CEOs' other companies
Preben Bruun-Nyzell – 6 other companies, of which 2 bankrupt
- 2N Pharma ApS Bankrupt 27 Apr 2026
- 2N Pharma Holding ApS Bankrupt 27 Apr 2026
- 2A Pharma ApS Active
- JTP HANDEL ApS Opløst
- SRS FOOD-SERVICE A/S Fusioneret
- SRS SERVICE & RENGØRINGS SELSKAB A/S Fusioneret
Josephus Dirk Vestergaard Nieland – 10 other companies, of which 4 bankrupt
- 2N Pharma ApS Bankrupt 27 Apr 2026
- 2N Pharma Holding ApS Bankrupt 27 Apr 2026
- AC 2,0 ApS Bankrupt 28 Jun 2023
- ACINDRIA ApS Bankrupt 16 Jun 2022
- 2A Pharma ApS Active
- AC 2,0 Holding ApS Active
- CPT.one BIOTECH ApS Fusioneret
- FIRMA AF 2008 ApS Opløst
- MALERFIRMAET BENT PEDERSEN A/S Active
- METANOVI ApS Opløst
Address history (1 moves)
| Kaolinvej 5, 9220 Aalborg Øst | |
| Niels Jernes Vej 10, 9220 Aalborg Øst |
Former names
| Neurometa Therapeutics ApS | – now |
| Geysir Therapeutics ApS | – |
Other companies at the same address
- JV INVEST ApS Active
- MALERFIRMAET BENT PEDERSEN A/S Active
- TRYKIT ApS Compulsorily dissolved
Similar companies in Aalborg
- Biogenity ApS Aalborg Øst
- 2A Pharma ApS Aalborg Øst
- Methyl Detect ApS Aalborg Øst
- EEGTRAINING NORD ApS Vestbjerg
- DNASENSE ApS Aalborg Øst
- C4PAIN ApS Aalborg
- OLE USSING ApS Aalborg
- REDO-Neurosystems ApS Aalborg
- 2N Pharma ApS Aalborg Øst
- ClearDynamic ApS Nørresundby
- The Froglet IVS Aalborg
- EMProS IVS Gistrup
Questions and answers about Neurometa Therapeutics ApS
Has Neurometa Therapeutics ApS gone bankrupt?
No, Neurometa Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Neurometa Therapeutics ApS?
Our model estimates a bankruptcy risk of 5.9% over the next 12 months (high risk), which is 4.2 times the average for Danish companies.
Who is the CEO of Neurometa Therapeutics ApS?
Preben Bruun-Nyzell, Josephus Dirk Vestergaard Nieland, Steinunn Sara Helgudóttir are the CEOs of Neurometa Therapeutics ApS.
Who is the auditor of Neurometa Therapeutics ApS?
Neurometa Therapeutics ApS most recently used Deloitte Statsautoriseret Revisionspartnerselskab.
When was Neurometa Therapeutics ApS founded?
Neurometa Therapeutics ApS was founded on 2 January 2024.
What is the equity of Neurometa Therapeutics ApS?
Equity was DKK -264k according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.